CA2998490A1 - Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate - Google Patents

Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate Download PDF

Info

Publication number
CA2998490A1
CA2998490A1 CA2998490A CA2998490A CA2998490A1 CA 2998490 A1 CA2998490 A1 CA 2998490A1 CA 2998490 A CA2998490 A CA 2998490A CA 2998490 A CA2998490 A CA 2998490A CA 2998490 A1 CA2998490 A1 CA 2998490A1
Authority
CA
Canada
Prior art keywords
subject
condition
liver disease
phenylacetate
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998490A
Other languages
English (en)
French (fr)
Inventor
Christopher F. Rose
Marc-Andre Clement
Cristina R. Bosoi
Mariana Macedo Oliveira
Melanie TREMBLAY
Chantal BEMEUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of CA2998490A1 publication Critical patent/CA2998490A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2998490A 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate Abandoned CA2998490A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US62/233,002 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (1)

Publication Number Publication Date
CA2998490A1 true CA2998490A1 (en) 2017-03-30

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998490A Abandoned CA2998490A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Country Status (7)

Country Link
US (1) US20200206174A1 (enExample)
EP (1) EP3352748A4 (enExample)
JP (1) JP6989495B2 (enExample)
AU (1) AU2016325556B2 (enExample)
CA (1) CA2998490A1 (enExample)
HK (1) HK1257679A1 (enExample)
WO (1) WO2017053613A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
SG11201802987UA (en) * 2015-11-13 2018-05-30 Ocera Therapeutics Inc Formulation of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
WO2019226786A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
AU2020270106A1 (en) * 2019-05-09 2021-11-18 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2652187T3 (es) * 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) * 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate

Also Published As

Publication number Publication date
WO2017053613A1 (en) 2017-03-30
EP3352748A1 (en) 2018-08-01
JP6989495B2 (ja) 2022-01-05
EP3352748A4 (en) 2019-06-05
WO2017053613A8 (en) 2017-04-27
AU2016325556A1 (en) 2018-03-01
JP2018531929A (ja) 2018-11-01
AU2016325556B2 (en) 2023-02-16
HK1257679A1 (zh) 2019-10-25
US20200206174A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
AU2016325556B2 (en) Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US20220081391A1 (en) Methods
Lin et al. Opening a new time window for treatment of stroke by targeting HDAC2
JP5247469B2 (ja) タンシノンを用いた炎症性サイトカイン産生の阻害
Fink et al. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level
Rani et al. In vitro and in vivo studies reveal the beneficial effects of chlorogenic acid against ER stress mediated ER-phagy and associated apoptosis in the heart of diabetic rat
AU2016308641B2 (en) Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
Fang et al. Attenuated blood-brain barrier dysfunction by XQ-1H following ischemic stroke in hyperlipidemic rats
Ren et al. Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR
Wang et al. Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance
Jin et al. Propofol limits rat myocardial ischemia and reperfusion injury with an associated reduction in apoptotic cell death in vivo
Sun et al. Scutellarin attenuates doxorubicin‐induced cardiotoxicity by inhibiting myocardial fibrosis, apoptosis and autophagy in rats
US9949991B2 (en) Methods of treating aquaporin-mediated conditions
CN107848970B (zh) 岩藻糖苷酶抑制剂
Chen et al. Protective effect of oxyberberine against acute lung injury in mice via inhibiting RhoA/ROCK signaling pathway
Tian et al. Curcumin ameliorates lipid metabolic disorder and cognitive dysfunction via the ABCA1 transmembrane transport system in APP/PS1 double transgenic mice
Li et al. Salidroside attenuates cerebral ischemia/reperfusion injury by regulating TSC2-induced autophagy
Gu et al. Rosiglitazone attenuates early brain injury after experimental subarachnoid hemorrhage in rats
Harima et al. Effect of carvedilol against myocardial injury due to ischemia–reperfusion of the brain in rats
Wu et al. Gabapentin alleviates myocardial ischemia–reperfusion injury by increasing the protein expression of GABAARδ
Wu et al. Ginsenoside Rh2 inhibits CBP/p300-mediated FOXO3a acetylation and epilepsy-induced oxidative damage via the FOXO3a–KEAP1–NRF2 pathway
Vijikumar et al. Novel mitoNEET ligand NL-1 improves therapeutic outcomes in an aged rat model of cerebral ischemia/reperfusion injury
Talbot et al. Activation of kinin B1 receptor evokes hyperthermia through a vagal sensory mechanism in the rat
Rehni et al. Blockade of acid-sensing ion channels attenuates recurrent hypoglycemia-induced potentiation of ischemic brain damage in treated diabetic rats
Wang et al. 23-Hydroxytormentic acid reduces cerebral ischemia/reperfusion damage in rats through anti-apoptotic, antioxidant, and anti-inflammatory mechanisms

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210903

FZDE Discontinued

Effective date: 20240227